Climb Bio to host webcast highlighting CLYM116, IgA Nephropathy opportunity

Climb Bio (CLYM) announced details for the CLYM116 webcast event, which is set for Monday, September 29, 2025, at 8:00 a.m. ET. Climb Bio’s management team will be joined by leading nephrologist, Craig E. Gordon, MD, MS, who has over 20 years of experience treating patients with IgA nephropathy. The event will highlight the Company’s CLYM116 program, a preclinical-stage monoclonal antibody targeting APRIL, a key driver of pathogenic B cell activity in autoimmune diseases. CLYM116 is being developed for the treatment of IgAN and is the only known anti-APRIL approach to employ a ‘sweeper’ mechanism of action, which facilitates recycling of CLYM116 and elimination of APRIL, and may support the potential for CLYM116 to demonstrate best-in-class efficacy, with less frequent dosing. The Company remains on track to file an IND or CTA for CLYM116 in the second half of 2025. The CLYM116 event will feature: An overview of IgAN, including unmet needs and the potential IgAN commercial opportunity; Preclinical data, including head-to-head nonhuman primate results, comparing CLYM116 to a first-generation anti-APRIL monoclonal antibody; and The Company’s development strategy and objectives for CLYM116.